Text Size

Vaccine Therapy in Treating Patients With Unresectable Metastatic Melanoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00004148
First received: December 10, 1999
Last updated: February 8, 2013
Last verified: June 2006
History of Changes
  Purpose

Phase I trial to study the effectiveness of vaccine therapy in treating patients who have unresectable metastatic melanoma. Vaccines may make the body build an immune response to kill tumor cells.


Condition Intervention Phase
Melanoma (Skin)
 Biological: recombinant vaccinia-B7.1 vaccine
 Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Trial of Intra Lesional RV-B7.1 Vaccine in the Treatment of Malignant Melanoma

Resource links provided by NLM:

MedlinePlus related topics: Cancer Melanoma
U.S. FDA Resources

Further study details as provided by National Cancer Institute (NCI):

Enrollment: 12
Study Start Date: October 1999
Primary Completion Date: April 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm I
Patients receive rV-B7.1 intralesionally every 4 weeks for 8 weeks (weeks 0, 4, and 8). Treatment continues every 12 weeks in the absence of unacceptable toxicity or disease progression for up to 2 courses. Cohorts of 6-8 patients receive escalating doses of vaccine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 or 3 of 8 patients experience dose limiting toxicities.
 Biological: recombinant vaccinia-B7.1 vaccine

Detailed Description:

OBJECTIVES:

I. Determine the maximum tolerated dose of the rV-B7.1 vaccine that elicits a host immune response and is associated with acceptable toxicity in patients with malignant metastatic melanoma.

II. Determine all clinical toxicities associated with this regimen in this patient population.

III. Determine the safety of this regimen in this patient population. IV. Assess evidence of host antimelanoma immune reactivity following this regimen.

V. Determine the effect of this regimen on T-cell immunity. VI. Assess the clinical response in this patient population receiving this regimen.

VII. Evaluate quality of life of these patients during this regimen.

OUTLINE: This is a dose escalation study.

Patients receive rV-B7.1 intralesionally every 4 weeks for 8 weeks (weeks 0, 4, and 8). Treatment continues every 12 weeks in the absence of unacceptable toxicity or disease progression for up to 2 courses. Cohorts of 6-8 patients receive escalating doses of vaccine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 or 3 of 8 patients experience dose limiting toxicities.

Quality of life is assessed before treatment, every 4 weeks, and at end of treatment. Patients are followed every 3 months.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically proven metastatic, unresectable melanoma Dermal, subcutaneous, or lymph node metastases
  • Accessible for injection
  • Lesions must measure at least 1 cm
  • Patients with no prior treatment allowed

  • Patients must have one of the following as proof of prior vaccinia immunization:

    • Physician certification
    • Recollection and appropriate vaccination scar site
    • No encephalitis, untreated cerebral metastases, other structural brain lesions, or leptomeningeal disease
    • No ascites or pleural effusions
    • No leukemia or lymphoma

PATIENT CHARACTERISTICS:

  • Age: Over 18
  • Performance status: ECOG 0-1 Karnofsky 80-100%
  • Life expectancy: Greater than 3 months
  • WBC greater than 4,000/mm3
  • Platelet count greater than 100,000/mm3
  • Hemoglobin greater than 10g/dL
  • Bilirubin less than 1.5 mg/dL
  • Transaminases no greater than 2 times upper limit of normal (ULN)
  • Alkaline phosphatase no greater than 2 times ULN
  • PT/PTT no greater than 2 fold elevation in patients not receiving anticoagulation medications
  • No alcoholic cirrhosis
  • Creatinine less than 2.0 mg/dL OR creatine clearance greater than 60 mL/min
  • No congestive heart failure
  • No serious cardiac arrhythmias
  • No recent prior myocardial infarction
  • No clinical coronary artery disease
  • No chronic obstructive pulmonary disease
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No seizure disorders
  • No underlying immunosuppressive disorder
  • No autoimmune disease HIV negative
  • No skin diseases
  • No open wounds
  • No eczema or other contraindications to vaccinia virus administration
  • Patients must be able to avoid high risk individuals (e.g., immunosuppressed patients, children under 3 years, pregnant women, patients with active or a history of eczema, or patients with other skin conditions) for 7-10 days following treatment
  • No significant allergy or hypersensitivity to eggs
  • No active or chronic infections
  • No concurrent medical illness
  • No other significant medical disease which would increase risk to patient
  • No other prior malignancy within the past 5 years except stage I carcinoma of the cervix or basal cell carcinoma

PRIOR CONCURRENT THERAPY:

  • At least 8 weeks since prior immunotherapy and recovered
  • No prior live pox virus vector
  • No more than 2 prior chemotherapy regimens
  • At least 4 weeks since prior chemotherapy and recovered
  • At least 4 weeks since prior systemic corticosteroids
  • No systemic corticosteroids for concurrent illness
  • No concurrent immunosuppressive steroids
  • At least 2 weeks since prior radiotherapy and recovered (no bone marrow toxicity)
  • At least 6 months since prior radiotherapy for brain metastases and recovered
  • At least 4 weeks since prior surgery for management of the primary or metastatic lesions and recovered with remaining measurable disease
  • At least 6 months since prior surgery for brain metastases and recovered
  • No concurrent immunosuppressive drugs
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00004148

Locations
United States, New York
Albert Einstein Comprehensive Cancer Center
Bronx, New York, United States, 10461
Sponsors and Collaborators
National Cancer Institute (NCI)
Investigators
Study Chair: Howard L. Kaufman, MD Albert Einstein College of Medicine of Yeshiva University
  More Information

Additional Information:
Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site

Publications:

Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00004148     History of Changes
Other Study ID Numbers: CDR0000067380, AECM-99-101, NCI-T99-0006
Study First Received: December 10, 1999
Last Updated: February 8, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by National Cancer Institute (NCI):
stage III melanoma
stage IV melanoma
recurrent melanoma

Additional relevant MeSH terms:
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
 Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas

ClinicalTrials.gov processed this record on May 19, 2013